Merck R&D

Photo
24.11.2022 • News

Germany’s Merck Realigns Drug R&D Strategy

In a move to advance productivity, the healthcare division of Germany’s Merck is realigning its drug discovery and launch strategy. Global healthcare research chief Danny Bar-Zohar told a conference call this week that the Darmstadt-based company will seek to strike a new balance between in-house R&D and external collaboration.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.